Clinical advances in hematology & oncology : H&O
The most recent articles from:
Clin Adv Hematol Oncol
-
Clin Adv Hematol Oncol · Oct 2014
ReviewPlatinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice?
Triple-negative breast cancer (TNBC) carries a higher risk of distant recurrence and death in the first 5 years compared with other types of breast cancer. Owing to the largely heterogeneous nature of TNBC, no unifying alteration exists that could benefit from a specific targeted therapy. ⋯ The utility of platinum agents in addition to standard adjuvant or neoadjuvant chemotherapy remains controversial, however, because data on overall survival and disease-free survival are not available. It remains unclear whether the addition of platinum agents to neoadjuvant chemotherapy improves long-term outcomes of TNBC.